Regulation of CYP3A4 and CYP3A5 expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor

被引:21
|
作者
Maguire, Orla [1 ]
Pollock, Catherine [1 ]
Martin, Philip [2 ]
Owen, Andrew [2 ]
Smyth, Thomas [1 ]
Doherty, Declan [1 ]
Campbell, Moray J. [3 ]
McClean, Stephen [1 ]
Thompson, Paul [1 ]
机构
[1] Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland
[2] Univ Liverpool, Dept Pharmacol, Liverpool L69 3GF, Merseyside, England
[3] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA
基金
英国生物技术与生命科学研究理事会;
关键词
Vitamin D receptor; Prostate; Metabolism; CYP3A4; CYP3A5; HUMAN LIVER-MICROSOMES; PREGNANE-X-RECEPTOR; CYTOCHROME-P450; 3A4; CANCER CELLS; RADICAL PROSTATECTOMY; CLINICAL PRESENTATION; PROTEASE INHIBITOR; GENE POLYMORPHISMS; IN-VITRO; RISK;
D O I
10.1016/j.mce.2012.08.007
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
We investigated the capacity for vitamin D receptor (VDR) to modulate the expression of CYP3A4 and other genes that may facilitate the oxidative inactivation of androgens such as testosterone and androstanediol within prostate cells. We report that exposure to the active hormonal form of vitamin D markedly increased gene expression of CYP3A4 and CYP3A5 and ultimately achieved levels of intracellular CYP3A enzyme activity within LNCaP prostate cancer cells that were comparable to that observed for Caco2 cells, an established model of CYP3A induction, and resulted in the increased turnover of testosterone to its inactive 6 beta-OH metabolite. We demonstrate that VDR directs CYP3A4 and CYP3A5 expression through binding to distinct regulatory motifs located within the 5' promoter regions of both genes. The current data highlight the potential application of VDR-based treatment regimes as a means to limit the bioavailability of growth-promoting androgens within the tumor microenvironment. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:54 / 64
页数:11
相关论文
共 50 条
  • [31] Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes
    Leel, Jin Sol
    Cheong, Hyun Sub
    Kim, Lyoung Hyo
    Kixn, Ji On
    Seo, Doo Won
    Kim, Young Hoon
    Chung, Myeon Woo
    Han, Soon Young
    Shin, Hyoung Doo
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2013, 17 (06): : 479 - 484
  • [32] NEW TOOLS TO DIFFERENTIATE CYP3A4 AND CYP3A5 ACTIVITY
    Li, Xiaohai
    Kamenecka, Theodore M.
    Jeso, Valer
    Micalizio, Glen
    Heyward, Scott
    Walker, Gregory S.
    Cameron, Michael D.
    DRUG METABOLISM REVIEWS, 2015, 47 : 70 - 70
  • [33] Differential inhibition of CYP3A4 and CYP3A5 by verapamil.
    Wang, Y
    Jones, DR
    Hall, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P16 - P16
  • [34] GLOBAL ANALYSIS OF CYP3A4 AND CYP3A5 GENOTYPE ON IN VIVO CLEARANCE OF CYP3A4 SUBSTRATES.
    Quinney, S. K.
    Schwartz, J. B.
    Hall, S. D.
    Gorski, J. C.
    Li, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S49 - S49
  • [35] Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
    Williams, JA
    Ring, BJ
    Cantrell, VE
    Jones, DR
    Eckstein, J
    Ruterbories, K
    Hamman, MA
    Hall, SD
    Wrighton, SA
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (08) : 883 - 891
  • [36] CYP3A5 and not CYP3A4 is present in peripheral blood.
    Janardan, SK
    Lown, KS
    SchmiedlinRen, P
    Watkins, PB
    GASTROENTEROLOGY, 1996, 110 (04) : A1222 - A1222
  • [37] Analysis of genotype, MRNA and protein expression of CYP3A4 and CYP3A5 in human liver
    Czerwinski, M
    Lyon, K
    Mudra, D
    Madan, A
    van Schaik, R
    Gaedigk, A
    Parkinson, A
    DRUG METABOLISM REVIEWS, 2002, 34 : 149 - 149
  • [38] Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: A possible role of intestinal CYP3A4 expression
    Ufer, M.
    Dilger, K.
    Leschhorn, L.
    Daufresne, L. M.
    Mosyagin, I.
    Rosenstiel, P.
    Haesler, R.
    Kuehbacher, T.
    Nikolaus, S.
    Schreiber, S.
    Cascorbi, I.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (01) : 43 - 46
  • [39] Regulatory variants in a novel distal enhancer regulate the expression of CYP3A4 and CYP3A5
    Collins, Joseph M.
    Nworu, Adaeze C.
    Mohammad, Somayya J.
    Li, Liang
    Li, Chengcheng
    Li, Chuanjiang
    Schwendeman, Ethan
    Cefalu, Mattew
    Abdel-Rasoul, Mahmoud
    Sun, Jessie W.
    Smith, Sakima A.
    Wang, Danxin
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (11): : 2720 - 2731
  • [40] APPLICATION OF THE CYP3A4 SELECTIVE MECHANISM-BASED INACTIVATOR CYP3CIDE TO DELINEATE CYP3A4 AND CYP3A5 CONTRIBUTIONS TO THE METABOLISM OF CYP3A CLEARED DRUGS
    Tseng, Elaine
    Walsky, Robert L.
    Luzietti, Rick
    Harris, Jennifer
    Kosa, Rachel E.
    Zientek, Michael A.
    Goosen, Theunis C.
    Obach, R. Scott
    DRUG METABOLISM REVIEWS, 2014, 45 : 77 - 77